The effect of Palmitoylethanolamide on the treatment of negative symptoms in patients with chronic schizophrenia

Palmitoylethanolamide as adjuvant therapy in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double blind and placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N127

Enrollment

Registered

2020-05-18

Start date

2020-06-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Palmitoylethanolamide capsule (ACECR, Tehran), 600 mg, BID, for 8 weeks. Intervention 2: Control group: Placebo (BID) for 8 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 60 years Take Risperidone for at least 4 weeks at the dose of 4-6 mg/day before entering the study The positive and acute symptoms of patients should be stable

Exclusion criteria

Exclusion criteria: Head trauma History of shock therapy during past three months prior to the trial Undergoing neurosurgery Presence of acute or chronic systemic diseases History of allergy to Cilostazol

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026